CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Products  /  Key Therapeutic Areas  /  Diabetes

KEY THERAPEUTIC AREAS

Diabetes

Diabetes is accelerating at an alarming rate globally. Today, over 475 million people across all age groups and social classes, live with the chronic condition. What is even more worrying is the fact that this mostly goes undetected until it reaches life-threatening proportions.

The constant monitoring, apart from the actual treatment, makes diabetes management an expensive process. As a credible, global player in the area of diabetes, Biocon is committed to making therapies for diabetes management increasingly affordable and accessible across the globe.

null

Biosimilars

Recombinant human Insulin

Insugen®, the world’s first recombinant human insulin (rh-Insulin) developed on a proprietary Pichia pastoris platform, was introduced in India in 2004.

Insugen® is among the Top 3 rh-Insulin brands in India.

Our rh-Insulin is currently registered in over 40 countries and has been commercialised in many emerging markets. Biocon has provided over 2 billion doses of rh-Insulin worldwide, so far.

 

Insulin Glargine

Biocon launched Insulin Glargine under the brand name Basalog® in 2009, providing an advanced, affordable, long-acting insulin analog to diabetes patients in India.

Insulin Glargine is approved in over 60 countries including Australia, Russia, Mexico, South Korea and Malaysia.

 

Insulin Aspart

Marketing Authorisation Application for biosimilar Insulin Aspart has been filed in the EU, where it is currently under review.

null

null

Novel Biologics

Insulin Tregopil

Insulin Tregopil, a first-in-class oral insulin molecule being developed by Biocon, is one of the most advanced programs in the global oral insulin space. It has completed a Phase II study in Type 2 diabetes patients in India.

Insulin Tregopil is undergoing a multiple ascending dose study in Type 1 diabetes patients in Germany, in partnership with the U.S.-based JDRF, a leading global organisation funding Type 1 diabetes research and advocacy worldwide.

Generics

Biocon offers a strong portfolio of generic APIs for diabetes that include:

  • Vildagliptin
  • Linagliptin
  • Sitagliptin (various salts)
  • Dapagliflozin (different solvate forms)
  • Empagliflozin
  • Repaglinide
  • Liraglutide
  • Semaglutide

The leader in Insulins

1st company globally to develop rh-insulin using a proprietary yeast platform based on Pichia pastoris.

1st company from India to get approval for and commercialise biosimilar Insulin Glargine in Japan.

1st company from India to commercialise biosimilar Insulin Glargine in Australia through the Pharmaceutical Benefits Scheme (PBS).

OUR LEGACY
GENERICS
WHO WE ARE
PRESS RELEASES
OUR CULTURE
Share